论文部分内容阅读
成都地奥制药公司的治疗心血管病植物新药——地奥心血康,是中科院成都生物研究所承担的六五、七五攻关课题。经过科技人员数年的艰辛劳动,此研究荣获中科院1988年度科技进步一等奖。获奖以后怎么办?成都生物所决定将成果转化为商品,这一决定得到中科院的大力支持,1988年10月,中国科技促进经济发展基金会给予贷款60万元筹建成都地奥公司。有了这60万,生物所科技人员凭着聪明才智,艰苦创业,无私奉献,勇闯“禁区”。公司创办6年多来,通过滚雪球创业,取得了令人瞩目的成绩,至今累积产值达8亿
Chengdu Diao Pharmaceutical Co., Ltd.’s new drug for treating cardiovascular diseases - Di Ao Xin Xuekang, is the subject of the 6th and 7th Five-Year Studies undertaken by Chengdu Institute of Biology, Chinese Academy of Sciences. After several years of hard work by scientific and technical personnel, this research won the first prize of the 1988 Scientific and Technological Progress Award of the Chinese Academy of Sciences. After winning the award, Chengdu Biology Institute decided to transform the achievement into a commodity. This decision was strongly supported by the Chinese Academy of Sciences. In October 1988, the China Science and Technology Foundation for Economic Development granted a loan of 600,000 yuan to build the company. With these 600,000 people, the Bioscience and Science staffs have been smart, talented, entrepreneurial, selfless, and courageous. Founded more than six years ago, the company has achieved remarkable results through snowball ventures, and the cumulative output value has reached 800 million so far.